Clinical trial
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric…
NCT00240994 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00240994 |
|---|---|
| Title | Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients |
| Official title | A Phase II Exploratory Study to Determine the Safety and Study the Immunomodulatory Functions of Induction Therapy With Campath, Combined With Chronic Immunosuppression With Mycophenolate Mofetil and Sirolimus |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Cooperative Clinical Trials in Pediatric Transplantation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression |
| Intervention type | Drug |
| Interventions | Alemtuzumab, Tacrolimus, Mycophenolate mofetil, Sirolimus |
| Enrollment | 35 |
| Start date | Jan 1, 2005 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Oct 18, 2005 |
| Last update posted | Jan 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: